| Type 2 Diabetes Mellitus |
1 |
1 |
| Biologic Therapy |
0 |
0.76 |
| Body Mass Index |
0 |
0.71 |
| Genomic Medicine |
0 |
0.7 |
| SGLT2 Inhibitor |
0 |
0.52 |
| Patient Safety |
0 |
0.41 |
| Nucleoside Reverse Transcriptase Inhibitors |
0 |
0.35 |
| Precision Medicine |
0 |
0.35 |
| DPP-4 Inhibitors |
0 |
0.33 |
| Weight Management |
0 |
0.3 |
| Adverse Effects |
0 |
0.29 |
| Chronic Kidney Disease |
0 |
0.23 |
| Renal Failure |
0 |
0.23 |
| Weight Gain |
0 |
0.23 |
| Heart Failure (HF) |
0 |
0.21 |
| Cardiovascular Risk Management |
0 |
0.2 |
| Renal Disease |
0 |
0.17 |
| Cardiovascular disease |
0 |
0.12 |
| Kidney |
0 |
0.12 |
| Kidney, Ureter, and Bladder |
0 |
0.12 |
| Sulfonylureas |
0 |
0.12 |
| GLP-1 Receptor Agonist |
0 |
0.1 |
| Obesity |
0 |
0.07 |
| Board Certification |
0 |
0.06 |
| Clinical Management |
0 |
0.06 |
| Clinical Research |
0 |
0.06 |
| Dorsum |
0 |
0.06 |
| Endocrinology |
0 |
0.06 |
| Europe |
0 |
0.06 |
| Evidence-Based Medicine |
0 |
0.06 |
| Heart |
0 |
0.06 |
| Hospital |
0 |
0.06 |
| Hyperglycemia |
0 |
0.06 |
| Molecular Medicine |
0 |
0.06 |
| Primary Care |
0 |
0.06 |
| Receptors |
0 |
0.06 |
| Shared Decision-Making |
0 |
0.06 |
| Stress |
0 |
0.06 |
| Tolerance |
0 |
0.06 |
| UK Site Content |
0 |
0.06 |